These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1511 related articles for article (PubMed ID: 15635109)

  • 1. C-reactive protein levels and outcomes after statin therapy.
    Ridker PM; Cannon CP; Morrow D; Rifai N; Rose LM; McCabe CH; Pfeffer MA; Braunwald E;
    N Engl J Med; 2005 Jan; 352(1):20-8. PubMed ID: 15635109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-reactive protein levels and outcomes after statin therapy.
    Clearfield M
    Curr Atheroscler Rep; 2006 Jan; 8(1):8-9. PubMed ID: 16455006
    [No Abstract]   [Full Text] [Related]  

  • 3. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
    Nissen SE; Tuzcu EM; Schoenhagen P; Crowe T; Sasiela WJ; Tsai J; Orazem J; Magorien RD; O'Shaughnessy C; Ganz P;
    N Engl J Med; 2005 Jan; 352(1):29-38. PubMed ID: 15635110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial.
    Ridker PM; Morrow DA; Rose LM; Rifai N; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2005 May; 45(10):1644-8. PubMed ID: 15893181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
    LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
    N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
    Cannon CP; Braunwald E; McCabe CH; Rader DJ; Rouleau JL; Belder R; Joyal SV; Hill KA; Pfeffer MA; Skene AM;
    N Engl J Med; 2004 Apr; 350(15):1495-504. PubMed ID: 15007110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
    Ray KK; Cannon CP; Cairns R; Morrow DA; Ridker PM; Braunwald E
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):424-30. PubMed ID: 19122170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study).
    Khera AV; Wolfe ML; Cannon CP; Qin J; Rader DJ
    Am J Cardiol; 2010 Aug; 106(4):451-6. PubMed ID: 20691300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
    LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
    Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
    Ray KK; Cannon CP; Cairns R; Morrow DA; Rifai N; Kirtane AJ; McCabe CH; Skene AM; Gibson CM; Ridker PM; Braunwald E;
    J Am Coll Cardiol; 2005 Oct; 46(8):1417-24. PubMed ID: 16226164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy.
    Mega JL; Morrow DA; Cannon CP; Murphy S; Cairns R; Ridker PM; Braunwald E
    J Thromb Thrombolysis; 2006 Aug; 22(1):71-6. PubMed ID: 16786236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
    Athyros VG; Mikhailidis DP; Papageorgiou AA; Symeonidis AN; Daskalopoulou SS; Kakafika AI; Pehlivanidis AN; Bouloukos VI; Langer A;
    Curr Med Res Opin; 2004 Sep; 20(9):1385-92. PubMed ID: 15383187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
    Murphy SA; Cannon CP; Wiviott SD; McCabe CH; Braunwald E
    J Am Coll Cardiol; 2009 Dec; 54(25):2358-62. PubMed ID: 20082923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
    Rouleau J
    Am J Med; 2005 Dec; 118 Suppl 12A():28-35. PubMed ID: 16356805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and design of assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction (the ALPS-AMI) study.
    Kashima Y; Izawa A; Aizawa K; Koshikawa M; Kasai H; Tomita T; Kumazaki S; Tsutsui H; Koyama J; Ikeda U
    J Cardiol; 2009 Aug; 54(1):76-9. PubMed ID: 19632524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
    Murphy SA; Cannon CP; Wiviott SD; de Lemos JA; Blazing MA; McCabe CH; Califf RM; Braunwald E
    Am J Cardiol; 2007 Oct; 100(7):1047-51. PubMed ID: 17884359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
    Kinlay S; Schwartz GG; Olsson AG; Rifai N; Leslie SJ; Sasiela WJ; Szarek M; Libby P; Ganz P;
    Circulation; 2003 Sep; 108(13):1560-6. PubMed ID: 12975259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. hsCRP and HDL effects of statins trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels A clinical investigation.
    Ansell BJ; Watson KE; Weiss RE; Fonarow GC
    Heart Dis; 2003; 5(1):2-7. PubMed ID: 12549983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy.
    Wiviott SD; Cannon CP; Morrow DA; Ray KK; Pfeffer MA; Braunwald E;
    J Am Coll Cardiol; 2005 Oct; 46(8):1411-6. PubMed ID: 16226163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 76.